Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miltefosine + paromomycin
- Development stage
- Unknown
- Lead developer
- Drugs for Neglected Diseases initiative
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Miltefosine + paromomycin is a combination therapy used for the treatment of visceral leishmaniasis, particularly in eastern Africa. This combination offers an alternative to the standard sodium stibogluconate plus paromomycin (SSG/PM) treatment. The combination provides similar efficacy to SSG/PM but with fewer injections, shorter treatment duration (14 days vs 17 days), and no risk of SSG-associated life-threatening cardiotoxicity, making it a more patient-friendly option for both children and adults. The combination also appears to reduce the risk of subsequent post-kala-azar dermal leishmaniasis (PKDL), which is important for reducing community transmission of visceral leishmaniasis.
- Other names
- PM/MFMF+PM
02
Targets
Ergosterol80S A-site (Eukaryotic ribosomal aminoacyl-tRNA site (A-site))
Beyond the preview
Go deeper on miltefosine + paromomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miltefosine + paromomycin.